Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Arterial Function Parameters and Transcranial Doppler Velocity in Paediatric Patients With Sickle Cell Disease

The Relationship of Transcranial Doppler Velocity With Other Vascular Measurements in Children With Sickle Cell Anaemia

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Structural and functional changes in arteries are increasingly being recognized as significant features of sickle cell disease. This study aims to determine whether there are differences in arterial function parameters between children with sickle cell disease with normal and abnormal transcranial Doppler velocity. After informed consent is obtained, participants will have vascular, Transcranial Doppler, haematological and biochemical parameters measured. Researchers will compare children with sickle cell disease who have normal Transcranial Doppler velocity and no history of stroke with children with those who have an abnormal Transcranial Doppler velocity with or without a history of stroke to see if there are significant differences in arterial function parameters.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Pediatric participants with sickle cell anaemia (HbSS, HbSβ0 thalassemia, HbSD, HbSOArab) 2. Age: Between 4-16 years of age, at the time of enrolment 3. Has had at least one complete TCD study whether or not on hydroxyurea treatment or in a clinical trial. 4. Parent or guardian willing and able to provide willing to sign a consent form and child gives assent 5. Ability to comply with study-related evaluations. Who Should NOT Join This Trial: - Participants who meet any of the following criteria are disqualified from enrollment in the study: 1. Patients in whom a TCD study cannot be completed 2. Patients who have had an Erythrocyte transfusion in the past two months 3. Patients who are acutely ill or have had an acute infection in the past two weeks Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Pediatric participants with sickle cell anaemia (HbSS, HbSβ0 thalassemia, HbSD, HbSOArab) 2. Age: Between 4-16 years of age, at the time of enrolment 3. Has had at least one complete TCD study whether or not on hydroxyurea treatment or in a clinical trial. 4. Parent or guardian willing and able to provide informed consent and child gives assent 5. Ability to comply with study-related evaluations. Exclusion Criteria: * Participants who meet any of the following criteria are disqualified from enrollment in the study: 1. Patients in whom a TCD study cannot be completed 2. Patients who have had an Erythrocyte transfusion in the past two months 3. Patients who are acutely ill or have had an acute infection in the past two weeks

Locations (1)

Caribbean Institute for Health Research, The University of the West Indies
Kingston, Saint Andrew Parish, Jamaica